With Affy Deal Signed, Epigenomics Now Plans To Deliver Prostate Recurrence Test by H2 2007 | GenomeWeb

Epigenomics last week said it obtained a non-exclusive license from Affymetrix to access its microarray technology to develop array-based in vitro diagnostics for oncology.

The Berlin-based company can now transfer its diagnostic and prognostic tests for prostate and breast cancer • its first products for the molecular diagnostic market • onto Affy's platform to use in clinical trials so the US Food and Drug Administration can begin reviewing them sometime next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.